Nutra Pharma Revenue Growth Rates (NPHC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nutra Pharma Corp   (NPHC)
 

NPHC's Revenue Growth by Quarter and Year

Nutra Pharma 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NPHC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.03
1st Quarter March 0.03
FY 0.06

NPHCs Annual Revenue
Nutra Pharma 's Revenue in the fiscal year 2025 $ 0.26 millions
Nutra Pharma 's Revenue in the fiscal year 2024 $ 0.25 millions
Nutra Pharma 's Revenue in the fiscal year 2023 $ 0.21 millions
Nutra Pharma 's Revenue in the fiscal year 2022 $ 0.44 millions
Nutra Pharma 's Revenue in the fiscal year 2021 $ 0.06 millions




NPHC Revenue second quarter 2026 Y/Y Growth Comment
Nutra Pharma Corp reported drop in Revenue in the second quarter 2026 by -56.92% to $ 0.03 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Nutra Pharma Corp 's Revenue compares unfavorably to the Company's average Revenue jump of 42.61%.

Looking into second quarter 2026 results within Legal Cannabis industry 8 other companies have achieved higher Revenue growth. While Nutra Pharma Corp ' s Revenue meltdown of -56.92% ranks overall at the positon no. 1325 in the second quarter 2026.


NPHC Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -62.5 % 60 % -77.27 %
3rd Quarter September - 0 % 40 % -54.55 %
2nd Quarter June -56.92 % 60 % 0 % -44.44 %
1st Quarter March -57.14 % 75 % -20 % 150 %
FY   - 4.17 % 20 % -

Financial Statements
Nutra Pharma 's second quarter 2026 Revenue $ 0.03 millions NPHC's Income Statement
Nutra Pharma 's second quarter 2025 Revenue $ 0.08 millions Quarterly NPHC's Income Statement


NPHC Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -57.14 % 14.29 % 0 %
3rd Quarter September - -12.5 % 40 % 0 %
2nd Quarter June 14.88 % 14.29 % 25 % 0 %
1st Quarter March 0 % -12.5 % -20 % -77.27 %
FY (Year on Year)   - 4.17 % 20 % -


Back to NPHC Growth rate Comparisons >> Back to NPHC Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #9
Consumer Non Cyclical Sector #46
Overall #1325

Revenue Y/Y Growth Statistics
High Average Low
834.31 % 42.61 % -116.85 %
(Jun 30 2021)   (Sep 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #9
Consumer Non Cyclical Sector #46
Overall #1325
Revenue Y/Y Growth Statistics
High Average Low
834.31 % 42.61 % -116.85 %
(Jun 30 2021)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nutra Pharma 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1101.38 % 36.18 % -90.64 %
(Dec 31 2012)  


NPHC's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Nutra Pharma Corp disclosed increase in Revenue from the first quarter by 14.88% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Legal Cannabis industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Nutra Pharma 's Revenue growth quarter on quarter, overall rank is 2526.


Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #12
Consumer Non Cyclical Sector #89
Overall #2526
Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #12
Consumer Non Cyclical Sector #89
Overall #2526
Revenue Q/Q Growth Statistics
High Average Low
1101.38 % 36.18 % -90.64 %
(Dec 31 2012)  


NPHC's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Nutra Pharma Corp disclosed increase in Revenue from the first quarter by 14.88% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Legal Cannabis industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Nutra Pharma 's Revenue growth quarter on quarter, overall rank is 2526.


Nutra Pharma 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.16 $ 0.21 $ 0.26 $ 0.31 $ 0.32
Y / Y Revenue Growth (TTM) -49.01 % -25.36 % 4.59 % 46.89 % 67.67 %
Year on Year Revenue Growth Overall Ranking # 245 # 267 # 634 # 3333 # 3281
Seqeuential Revenue Change (TTM) -23.74 % -18.14 % -17.07 % -1.51 % 11.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 1325 # 945 # 775 # 1048 # 2174


Cumulative Revenue growth Comment
Nutra Pharma 's cumulative 12 months Revenue continue to drop, but on the faster rate at -49.01% year on year, at Jun 30 2026 compare to the -25.36% decrease at Mar 31 2026. If the Nutra Pharma 's fiscal year would end at Jun 30 2026, annual Revenue would be $0 millions.

Among companies within the Consumer Non Cyclical sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 245, from total ranking in previous quarter at 267.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 9
Consumer Non Cyclical Sector # 11
Overall # 245

Revenue TTM Y/Y Growth Statistics
High Average Low
834.31 %
 42.61 %
-116.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 46
S&P 500 # 1325
Cumulative Revenue growth Comment
Nutra Pharma 's cumulative 12 months Revenue continue to drop, but on the faster rate at -49.01% year on year, at Jun 30 2026 compare to the -25.36% decrease at Mar 31 2026. If the Nutra Pharma 's fiscal year would end at Jun 30 2026, annual Revenue would be $0 millions.

Among companies within the Consumer Non Cyclical sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 245, from total ranking in previous quarter at 267.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 9
Consumer Non Cyclical Sector # 11
Overall # 245

Revenue TTM Y/Y Growth Statistics
High Average Low
834.31 %
42.61 %
-116.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 46
S&P 500 # 1325




Other Revenue Growth
Legal Cannabis Industry Revenue Growth Trends and Statistics
Consumer Non Cyclical Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NPHC's Revenue Growth Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Consumer Non Cyclical SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Tyson Foods Inc -0.12%$ -0.115 millions
Tootsie Roll Industries Inc-0.17%$ -0.171 millions
Ascend Wellness Holdings, Inc.-0.93%$ -0.932 millions
Andersons Inc -1.22%$ -1.218 millions
Scotts Miracle gro Co-1.34%$ -1.338 millions
Kraft Heinz Co-1.42%$ -1.417 millions
Willamette Valley Vineyards Inc -1.56%$ -1.564 millions
Post Holdings Inc -1.83%$ -1.829 millions
The Marzetti Company-2.19%$ -2.187 millions
Smithfield Foods Inc -2.30%$ -2.297 millions
Pilgrim s Pride Corporation-2.76%$ -2.755 millions
The Boston Beer Company Inc -3.34%$ -3.335 millions
Niagen Bioscience Inc -4.28%$ -4.281 millions
Mosaic Co-6.04%$ -6.042 millions
J and j Snack Foods Corp -6.19%$ -6.186 millions
Beyond Meat Inc -7.72%$ -7.721 millions
Central Garden and Pet Company-8.09%$ -8.088 millions
Golden Growers Cooperative-8.38%$ -8.378 millions
American Vanguard Corporation-9.17%$ -9.174 millions
Biote Corp -9.48%$ -9.478 millions
Vital Farms Inc -9.66%$ -9.660 millions
Trulieve Cannabis Corp.-10.31%$ -10.306 millions
Reed s Inc -14.98%$ -14.977 millions
Longevity Health Holdings Inc -21.37%$ -21.370 millions
Solesence Inc -22.87%$ -22.866 millions
Upexi Inc -26.57%$ -26.574 millions
Medifast Inc -27.01%$ -27.006 millions
The Hain Celestial Group Inc -27.60%$ -27.599 millions
22nd Century Group inc -29.86%$ -29.855 millions
Hydrofarm Holdings Group Inc -40.17%$ -40.169 millions


About Nutra Pharma Revenue Growth Rates (NPHC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nutra Pharma Corp (CIK 1119643).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-039166
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nutra Pharma Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.